SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

A groundbreaking study has spotlighted SNAC, the key absorption enhancer in oral versions of Ozempic and Wegovy tablets, and its potential impact on gut microbiota. This is the first in vivo study to systematically investigate how repeated exposure to SNAC affects gut microbiota, metabolic function, and related health markers. Using an animal model over a 21-day period, scientists observed several notable changes, prompting questions about long-term effects as these convenient pill forms gain traction.

What is SNAC and Why Is It Used in Semaglutide Tablets?

Semaglutide, the active ingredient in widely used weight loss and diabetes medications like Wegovy and Ozempic, mimics the GLP-1 hormone to regulate blood sugar, slow gastric emptying, and reduce appetite. When administered via injection, semaglutide enters the bloodstream directly, bypassing the digestive system's harsh environment. However, in tablet form, it relies on SNAC—sodium N-(8-(2-hydroxybenzoyl) amino) caprylate—to protect it from stomach enzymes and facilitate absorption into the bloodstream.

Without SNAC, oral semaglutide would be rendered ineffective by rapid breakdown in the gut. The United States approved a tablet version of Wegovy late last year, making it a more convenient alternative to weekly injections. Pills are often perceived as easier to use and potentially less costly, which could lead to significantly higher daily exposure to SNAC as adoption increases worldwide.

The First In Vivo Study on SNAC's Effects

Study Design and Methodology

This pioneering research, conducted over 21 days in an animal model, marks the first systematic in vivo examination of SNAC's broader biological impacts. Researchers focused on repeated exposure, simulating the daily dosing typical of oral semaglutide regimens. Key areas assessed included gut microbiota composition, metabolic pathways, inflammatory responses, and markers of cognitive health.

Key Findings: Changes Beyond Drug Absorption

The study observed notable shifts: associations with potentially harmful gut bacteria, elevated inflammatory markers, and depletion of proteins linked to cognitive impairment. These changes suggest SNAC may influence the body in ways that extend far beyond enabling semaglutide absorption.

Importantly, the study does not prove that SNAC is harmful, particularly in humans. As animal research, results must be interpreted cautiously, but they highlight the need to evaluate all components of these therapies holistically.

Implications for Gut Health and Metabolic Function

The gut microbiota plays a crucial role in digestion, immune function, and even brain health via the gut-brain axis. Disruptions, such as increases in pathogenic bacteria or inflammation, could theoretically exacerbate conditions like irritable bowel syndrome, metabolic syndrome, or cognitive decline—common concerns in obesity patients.

While semaglutide itself offers proven benefits for weight loss and cardiovascular risk reduction, the addition of SNAC introduces new variables. Elevated inflammatory markers observed in the study could signal subtle systemic effects, warranting monitoring in long-term users. Proteins depleted in the model are associated with cognitive impairment, raising theoretical questions about neurological impacts, though human data is absent.

Rising Use of Oral Obesity Medications Amid Global Trends

Obesity remains a major global health issue, affecting around 890 million adults and 160 million children worldwide—roughly one in eight people. Among OECD countries, the United States leads with 43% of people aged 15 and older impacted, followed by Australia at 31%, above the OECD average of 25%.

Prescriptions for medications such as Ozempic and Wegovy have climbed rapidly in Australia in recent years, mirroring global surges. The shift to oral formulations could amplify SNAC exposure, as patients opt for daily pills over injections for convenience.

Expert Insights: Calls for Further Research

Lead author Amin Ariaee, a PhD candidate at Adelaide University, said the rapid expansion of oral obesity treatments that utilize SNAC makes it important to fully understand how every ingredient in these medications affects the body over time.

"Obesity is a complex, chronic disease with serious health consequences. These medicines are highly effective and are helping many people," Ariaee says.

"But as oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body -- not just the active drug.

"While SNAC enables semaglutide to be taken as a tablet, our study found that it was also associated with shifts in potentially harmful gut bacteria, elevated inflammatory markers and depletion of proteins linked to cognitive impairment. These findings warrant further investigation."

Senior Research Fellow Dr. Paul Joyce emphasized that the findings come from animal research and should be interpreted with caution.

"Importantly, our findings do not prove that SNAC causes harm in humans," Dr. Joyce says.

"However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption.

"These medicines are typically taken daily and often for long periods. As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound."

Oral vs. Injectable Semaglutide: A Comparison

Injectable Ozempic and Wegovy have established safety profiles from extensive clinical trials, focusing primarily on semaglutide. Oral versions introduce SNAC, which, while enabling convenience, lacks the same long-term human data. Injections may suit those prioritizing proven simplicity, while tablets appeal to needle-phobes—but patients should weigh potential gut effects.

Semaglutide tablets require fasting and specific administration to maximize absorption, adding adherence challenges compared to once-weekly shots.

Safety Considerations and Patient Guidance

Common semaglutide side effects include nausea, diarrhea, and constipation, often gut-related. This study adds context to monitor microbiota changes, perhaps via stool tests or symptom tracking apps like Shotlee for logging digestive issues alongside medication schedules.

Patients considering oral forms should discuss with their doctor: family history of gut disorders, concurrent medications, or cognitive concerns. Routine check-ups for inflammation (e.g., CRP levels) or microbiota could be prudent. Not everyone will experience issues, but awareness empowers informed choices.

Key Takeaways: What This Means for Patients

• The study is the first to explore SNAC's in vivo effects on gut microbiota, finding associations with harmful bacteria shifts, inflammation, and cognitive protein depletion in animals.
• SNAC enables oral semaglutide but may have broader impacts; human harm is not proven.
• As oral Wegovy tablets rise in popularity amid obesity epidemics, further research is essential.
• Consult healthcare providers before switching forms, and track symptoms diligently.
• Benefits of semaglutide remain strong, but holistic ingredient evaluation is key for long-term safety.

Conclusion

This study on SNAC in Ozempic and Wegovy tablets underscores the importance of scrutinizing every element of innovative therapies. While raising valid gut health questions, it reaffirms the need for balanced perspectives: celebrate efficacy while pursuing rigorous investigation. Patients, stay informed, communicate with providers, and prioritize comprehensive health monitoring to maximize benefits from these life-changing medications.